CBD Global Sciences Inc. (CBDNF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören CBD Global Sciences Inc. (CBDNF), 0 değerindeki bir Healthcare şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 38/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 18 Mar 2026CBD Global Sciences Inc. (CBDNF) Sağlık ve Boru Hattı Genel Bakışı
CBD Global Sciences Inc. operates in the CBD market, engaging in farming, processing, and manufacturing CBD products. With brands like Aethics and CannaOil, the company caters to the growing demand for CBD-based solutions, facing competition and regulatory challenges in the evolving healthcare landscape.
Yatırım Tezi
Investing in CBD Global Sciences Inc. presents a high-risk, high-reward scenario. The company's negative P/E ratio of -0.20 and a significantly negative profit margin of -3469.4% indicate substantial financial challenges. A gross margin of 24.6% suggests some ability to generate profit from sales, but operational inefficiencies weigh heavily. The company's beta of 0.43 suggests lower volatility compared to the market. Growth depends on successful brand building, market penetration, and navigating regulatory hurdles. Key catalysts include potential changes in legislation that could broaden market access and increased consumer acceptance of CBD products. The company's ability to scale operations efficiently and achieve profitability will be critical for long-term success.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $0.00B indicates the company's small size and potential for growth, but also higher risk.
- Negative P/E ratio of -0.20 reflects the company's current lack of profitability.
- Profit Margin of -3469.4% highlights significant operational challenges and high expenses relative to revenue.
- Gross Margin of 24.6% suggests potential for profitability if operational efficiencies are improved.
- Beta of 0.43 indicates lower volatility compared to the overall market.
Rakipler & Benzerleri
Güçlü Yönler
- Established brands: Aethics, CannaOil, and Strasburg Pharms.
- Vertically integrated operations.
- Proprietary formulations for CBD products.
Zayıflıklar
- Negative profitability and high operating expenses.
- Small market capitalization.
- Limited financial resources.
Katalizörler
- Upcoming: Potential changes in legislation that could broaden market access for CBD products.
- Ongoing: Increasing consumer acceptance of CBD products for wellness and therapeutic applications.
- Ongoing: Expansion of distribution networks and partnerships with retailers.
- Upcoming: Potential for new product launches and innovative formulations.
- Ongoing: Research and development efforts to explore new therapeutic applications of CBD.
Riskler
- Ongoing: Regulatory uncertainty and evolving legal landscape.
- Ongoing: Intense competition from established and emerging players.
- Potential: Fluctuations in raw material prices.
- Potential: Changing consumer preferences and market trends.
- Ongoing: Negative profitability and high operating expenses.
Büyüme Fırsatları
- Expansion into new therapeutic areas represents a significant growth opportunity for CBD Global Sciences Inc. The company can invest in research and development to explore the potential of CBD in addressing specific health conditions, such as anxiety, pain management, and sleep disorders. Positive clinical trial results and subsequent regulatory approvals could lead to the development of novel CBD-based therapies, opening up new revenue streams and market segments. This expansion requires strategic partnerships with research institutions and healthcare providers.
- Geographic market expansion offers another avenue for growth. CBD Global Sciences Inc. can target new regions with favorable regulatory environments and growing consumer demand for CBD products. This expansion could involve establishing distribution networks, partnering with local retailers, or setting up operations in new countries. Careful market research and adaptation of product offerings to local preferences are essential for success. The global CBD market is projected to reach billions of dollars in the coming years, providing ample opportunities for growth.
- Development of innovative CBD product formulations can drive revenue growth. CBD Global Sciences Inc. can invest in research and development to create new and improved CBD products, such as enhanced edibles, topical creams, and transdermal patches. These innovative products can cater to specific consumer needs and preferences, differentiating the company from competitors. Collaborations with formulation experts and technology providers can accelerate the development process and ensure product quality and efficacy.
- Strategic partnerships with established healthcare companies can provide access to new markets and distribution channels. CBD Global Sciences Inc. can collaborate with pharmaceutical companies, nutraceutical manufacturers, or healthcare providers to co-develop and market CBD products. These partnerships can leverage the expertise and resources of established players, accelerating market penetration and building brand credibility. Due diligence and careful negotiation are essential to ensure mutually beneficial partnerships.
- Focus on sustainable and ethical sourcing of CBD can enhance brand reputation and attract environmentally conscious consumers. CBD Global Sciences Inc. can implement sustainable farming practices, obtain certifications for organic and fair-trade CBD, and promote its commitment to environmental stewardship. This focus on sustainability can differentiate the company from competitors and appeal to a growing segment of consumers who prioritize ethical and environmentally responsible products. Transparency and traceability throughout the supply chain are crucial for building trust with consumers.
Fırsatlar
- Expansion into new therapeutic areas.
- Geographic market expansion.
- Development of innovative CBD product formulations.
- Strategic partnerships with established healthcare companies.
Tehditler
- Regulatory uncertainty and evolving legal landscape.
- Intense competition from established and emerging players.
- Fluctuations in raw material prices.
- Changing consumer preferences and market trends.
Rekabet Avantajları
- Brand recognition through Aethics, CannaOil, and Strasburg Pharms brands.
- Vertically integrated operations, controlling aspects of the supply chain from cultivation to product distribution.
- Proprietary formulations and manufacturing processes for CBD products.
CBDNF Hakkında
CBD Global Sciences Inc., established in 2018 and headquartered in Lakewood, Colorado, operates within the cannabidiol (CBD) sector. The company's core business revolves around CBD farming, processing, and the manufacturing of a diverse range of CBD products. These products are marketed under several brand names, including Aethics, CannaOil, and Strasburg Pharms. The company cultivates biomass, extracts CBD oil, and formulates various CBD-infused products aimed at capitalizing on the increasing consumer interest in CBD for wellness and therapeutic applications. CBD Global Sciences seeks to establish a vertically integrated operation, controlling aspects of the supply chain from cultivation to product distribution. The company aims to differentiate itself through product quality, branding, and strategic partnerships within the evolving CBD market.
Ne Yaparlar
- Farming of cannabidiol (CBD) biomass.
- Processing of CBD biomass to extract CBD oil.
- Manufacturing of CBD oil products.
- Marketing and sales of CBD products under the Aethics brand.
- Marketing and sales of CBD products under the CannaOil brand.
- Marketing and sales of CBD products under the Strasburg Pharms brand.
İş Modeli
- Cultivation of hemp to produce CBD-rich biomass.
- Extraction and refinement of CBD oil from the biomass.
- Formulation and manufacturing of various CBD products, including oils, tinctures, edibles, and topicals.
- Distribution and sale of CBD products through online channels, retail partnerships, and wholesale agreements.
Sektör Bağlamı
CBD Global Sciences Inc. operates within the rapidly evolving CBD industry, a segment of the broader healthcare market. The industry is characterized by increasing consumer demand for CBD products, driven by perceived wellness benefits. However, the market is also highly competitive, with numerous players vying for market share. Regulatory uncertainty remains a significant challenge, as laws governing CBD production, distribution, and marketing vary widely across jurisdictions. The company faces competition from established players in the pharmaceutical, nutraceutical, and consumer goods industries, as well as smaller, specialized CBD companies. Success in this market requires effective branding, product innovation, and navigating the complex regulatory landscape.
Kilit Müşteriler
- Consumers seeking CBD products for wellness and therapeutic purposes.
- Retailers and distributors of CBD products.
- Wholesale customers, including healthcare providers and other businesses.
Finansallar
Grafik & Bilgi
CBD Global Sciences Inc. (CBDNF) hisse senedi fiyatı: Price data unavailable
Son Haberler
CBDNF için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
CBDNF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
CBDNF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, CBDNF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Brad Wyatt
CEO
Brad Wyatt serves as the CEO of CBD Global Sciences Inc. His background includes experience in the cannabis and hemp industries, with a focus on business development and strategic partnerships. He has been involved in various aspects of the industry, from cultivation to product manufacturing and distribution. Wyatt's expertise lies in identifying market opportunities, building relationships with key stakeholders, and driving revenue growth. He has a track record of successfully launching new products and expanding market share in the competitive CBD market.
Sicil: Under Brad Wyatt's leadership, CBD Global Sciences Inc. has focused on expanding its product portfolio and distribution network. Key achievements include the development of new CBD product formulations and the establishment of partnerships with retailers and distributors. The company has also worked to enhance its brand recognition and build a loyal customer base. Wyatt has overseen the company's efforts to navigate the complex regulatory landscape and ensure compliance with all applicable laws and regulations.
CBDNF OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that CBDNF may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, defunct businesses, or companies with questionable operations.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure increases the risk of investing in CBDNF.
- Low trading volume and liquidity can lead to price volatility.
- Potential for fraud or manipulation is higher on the OTC market.
- OTC Other tier stocks are subject to less regulatory oversight.
- Difficulty in obtaining reliable information about the company's operations and financial condition.
- Verify the company's registration and legal standing.
- Attempt to obtain and review any available financial statements.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the regulatory environment in which the company operates.
- Evaluate the company's liquidity and trading volume.
- Consult with a qualified financial advisor.
- The company has been in operation since 2018.
- The company has established brands: Aethics, CannaOil, and Strasburg Pharms.
- The company has a CEO in place.
CBD Global Sciences Inc. Hissesi: Cevaplanan Temel Sorular
CBDNF için değerlendirilmesi gereken temel faktörler nelerdir?
CBD Global Sciences Inc. (CBDNF) şu anda yapay zeka skoru 38/100, düşük puanı gösteriyor. Temel güçlü yan: Established brands: Aethics, CannaOil, and Strasburg Pharms.. İzlenmesi gereken birincil risk: Ongoing: Regulatory uncertainty and evolving legal landscape.. Bu bir finansal tavsiye değildir.
CBDNF MoonshotScore'u nedir?
CBDNF şu anda MoonshotScore'da 38/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
CBDNF verileri ne sıklıkla güncellenir?
CBDNF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler CBDNF hakkında ne diyor?
CBDNF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
CBDNF'a yatırım yapmanın riskleri nelerdir?
CBDNF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Ongoing: Regulatory uncertainty and evolving legal landscape.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
CBDNF'ın P/E oranı nedir?
CBDNF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için CBDNF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
CBDNF aşırı değerli mi, yoksa düşük değerli mi?
CBD Global Sciences Inc. (CBDNF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
CBDNF'ın temettü verimi nedir?
CBD Global Sciences Inc. (CBDNF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited information available for OTC-listed companies.
- Financial data may be outdated or incomplete.